Regeneron Pharmaceuticals (REGN) said late Thursday its initial phase 1b trials data of linvoseltamab in combination with carfilzomib or bortezomib to treat refractory multiple myeloma showed a 90% objective response rate after a 15-month follow-up.
Almost 76% of patients achieved a complete response, the company said.
Adverse events were recorded in over 50% of the patients, while grade 3 adverse events included neutropenia, cytokine release syndrome, diarrhea, and thrombocytopenia. Infections developed in 91% of patients, and serious adverse events occurred in 83%.
The company will present trial data at the American Society of Clinical Oncology 2025 Annual Meeting on June 2.
Shares were down 2% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.